Adaptimmune Therapeutics Plc SEC Filings

Adaptimmune Therapeutics plc received a Schedule 13G from Long Focus Capital Management, LLC and John Helmers regarding its American Depositary Shares, each representing 6 ordinary shares. As of the close of business on December 31, 2025, the filing reports beneficial ownership of 0 ADS, representing 0% of the class, with no sole or shared voting or dispositive power.

The securities referenced were purchased in client accounts managed by Long Focus, and no individual client owns more than 5% of the class. The filers certify the holdings are in the ordinary course of business and not for influencing control of Adaptimmune.